Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial


Colombel J., Panaccione R., Bossuyt P., Lukas M., Baert F., Vanasek T., ...Daha Fazla

LANCET, cilt.390, sa.10114, ss.2779-2789, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 390 Konu: 10114
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/s0140-6736(17)32641-7
  • Dergi Adı: LANCET
  • Sayfa Sayıları: ss.2779-2789

Özet

Background Biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein, have been recommended for monitoring patients with Crohn's disease, but whether their use in treatment decisions improves outcomes is unknown. We aimed to compare endoscopic and clinical outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control algorithm, using clinical symptoms and biomarkers, versus patients managed with a clinical management algorithm.